The roles of CYP2C19 and CYP3A4 in the in vitro metabolism of β‐eudesmol in human liver: Reaction phenotyping and enzyme kinetics
Pharmacology Research & Perspectives · 2023
DOI: 10.1002/prp2.1149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2023. Verfasst von Nadda Muhamad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Studies, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme System. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Thailand Science Research and Innovation Fundamental Fund, Thammasat University Research Fund.
Abstract (Originalsprache)
β‐eudesmol is a major bioactive component of Atractylodes lancea (AL). AL has been developed as the capsule formulation of standardized AL extract for treating cholangiocarcinoma (CCA). However, the complex constituents of herbal products increase the risk of adverse drug interactions. β‐eudesmol has demonstrated inhibitory effects on rCYP2C19 and rCYP3A4 in the previous research. This study aimed to identify the cytochrome P450 (CYP) isoforms responsible for the metabolism of β‐eudesmol and determine the enzyme kinetic parameters and the metabolic stability of β‐eudesmol metabolism in the microsomal system. Reaction phenotyping using human recombinant CYPs (rCYPs) and selective chemical inhibitors of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 was performed, and enzyme kinetics and metabolic stability were investigated using human liver microsome (HLM). The results suggest that CYP2C19 and CYP3A4 play significant roles in β‐eudesmol metabolism. The disappearance half‐life ( t 1/2 ) and intrinsic clearance ( CL int ) of β‐eudesmol were 17.09 min and 0.20 mL/min·mg protein, respectively. Enzyme kinetic analysis revealed the Michaelis–Menten constant ( K m ) and maximum velocity ( V max ) of 16.76 μM and 3.35 nmol/min·mg protein, respectively. As a component of AL, β‐eudesmol, as a substrate and inhibitor of CYP2C19 and CYP3A4, has a high potential for drug–drug interactions when AL is co‐administered with other herbs or conventional medicines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Studies, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand.
- Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Thammasat University, Pathumthani, Thailand.
- Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathumthani, Thailand.
ORCID-Profile: Nadda Muhamad, Kesara Na-Bangchang
Förderung
- Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma
- Thailand Science Research and Innovation Fundamental Fund
- Thammasat University Research Fund
- The Thailand Research Fund under the Royal Golden Jubilee Ph.D. Program
Zitieren
APA
Muhamad, N., & Na-Bangchang, K. (2023). The roles of CYP2C19 and CYP3A4 in the in vitro metabolism of β‐eudesmol in human liver: Reaction phenotyping and enzyme kinetics. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1149
Vancouver
Muhamad N, Na-Bangchang K. The roles of CYP2C19 and CYP3A4 in the in vitro metabolism of β‐eudesmol in human liver: Reaction phenotyping and enzyme kinetics. Pharmacology Research & Perspectives. 2023. doi:10.1002/prp2.1149
BibTeX
@article{Muhamad2023,
author = {Muhamad, Nadda and Na-Bangchang, Kesara},
title = {The roles of CYP2C19 and CYP3A4 in the in vitro metabolism of β‐eudesmol in human liver: Reaction phenotyping and enzyme kinetics},
journal = {Pharmacology Research & Perspectives},
year = {2023},
doi = {10.1002/prp2.1149}
}
EUVIMED